Current Hypertension Reports

, Volume 6, Issue 2, pp 85–89 | Cite as

Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus

  • Dierk H. Endemann
  • Ernesto L. Schiffrin


The prevalence of diabetes mellitus is rising worldwide and has reached epidemic dimensions. Diabetes mellitus places patients at high cardiovascular risk. High blood glucose levels, altered insulin signaling, reactive oxygen species (ROS), inflammation, and protein kinase C activation might lead to a decrease in nitric oxide (NO) bioavailability. Diminished NO and enhanced oxidative stress play a central role in several pathophysiologic pathways, leading to vascular damage, such as endothelial dysfunction, vascular inflammation, atherosclerotic plaque formation and vulnerability, and promotion of a prothrombotic state. Possible sources of oxidative excess in diabetes are reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase, uncoupled NO synthase, and the mitochondria. Advances in understanding the pathophysiologic mechanisms leading to vascular damage in diabetes will result in discovery of new therapeutic targets, which should help reduce cardiovascular risk in these patients.

References and Recommended Reading

  1. 1.
    Narayan KM, Boyle JP, Thompson TJ, et al.: Lifetime risk for diabetes mellitus in the United States. JAMA 2003, 290:1884–1890.PubMedCrossRefGoogle Scholar
  2. 2.
    Rizzoni D, Porteri E, Guelfi D, et al.: Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001, 103:1238–1244.PubMedGoogle Scholar
  3. 3.
    Schofield I, Malik R, Izzard A, et al.: Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002, 106:3037–3043.PubMedCrossRefGoogle Scholar
  4. 4.
    Wen Y, Skidmore JC, Porter-Turner MM, et al.: Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes. Diabetes Obes Metab 2002, 4:305–308.PubMedCrossRefGoogle Scholar
  5. 5.
    Schram MT, Chaturvedi N, Schalkwijk C, et al.: Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003, 26:2165–2173.PubMedCrossRefGoogle Scholar
  6. 6.
    Heitzer T, Schlinzig T, Krohn K, et al.: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673–2678.PubMedGoogle Scholar
  7. 7.
    Stehouwer CD, Gall MA, Twisk JW, et al.: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002, 51:1157–1165. This study indicates urinary albumin excretion, endothelial dysfunction, and chronic inflammation as independent predictors of death in diabetes.PubMedCrossRefGoogle Scholar
  8. 8.
    Frisbee JC, Stepp DW: Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 2001, 281:H1304-H1311.PubMedGoogle Scholar
  9. 9.
    Kim YK, Lee MS, Son SM, et al.: Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 2002, 51:522–527.PubMedCrossRefGoogle Scholar
  10. 10.
    Popov D, Costache G, Georgescu A, Enache M: Beneficial effects of L-arginine supplementation in experimental hyperlipemia-hyperglycemia in the hamster. Cell Tissue Res 2002, 308:109–120.PubMedCrossRefGoogle Scholar
  11. 11.
    Yu PK, Yu DY, Cringle SJ, Su EN: Tetrahydrobiopterin reverses the impairment of acetylcholine-induced vasodilatation in diabetic ocular microvasculature. J Ocul Pharmacol Ther 2001, 17:123–129.PubMedCrossRefGoogle Scholar
  12. 12.
    Ouvina SM, La Greca RD, Zanaro NL, et al.: Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res 2001, 102:107–114.PubMedCrossRefGoogle Scholar
  13. 13.
    Tretjakovs P, Kalnins U, Dabina I, et al.: Nitric oxide production and arachidonic acid metabolism in platelet membranes of coronary heart disease patients with and without diabetes. Med Princ Pract 2003, 12:10–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Creager MA, Luscher TF, Cosentino F, Beckman JA: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003, 108:1527–1532. Comprehensive review on pathophysiologic mechanisms leading to vascular damage in diabetes.PubMedCrossRefGoogle Scholar
  15. 15.
    Sonoki K, Iwase M, Iino K, et al.: Atherogenic role of lysophosphatidylcholine in low-density lipoprotein modified by phospholipase A2 and in diabetic patients: protection by nitric oxide donor. Metabolism 2003, 52:308–314.PubMedCrossRefGoogle Scholar
  16. 16.
    Ramana KV, Chandra D, Srivastava S, et al.: Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells. FASEB J 2003, 17:417–425. This study suggests that NO is a regulator of the polyol pathway.PubMedCrossRefGoogle Scholar
  17. 17.
    Hamuro M, Polan J, Natarajan M, Mohan S: High glucose induced nuclear factor kappa B mediated inhibition of endothelial cell migration. Atherosclerosis 2002, 162:277–287.PubMedCrossRefGoogle Scholar
  18. 18.
    Napoli C, Lerman LO, de Nigris F, et al.: Glycoxidized lowdensity lipoprotein downregulates endothelial nitric oxide synthase in human coronary cells. J Am Coll Cardiol 2002, 40:1515–1522.PubMedCrossRefGoogle Scholar
  19. 19.
    Cosentino F, Hishikawa K, Katusic ZS, Luscher TF: High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997, 96:25–28.PubMedGoogle Scholar
  20. 20.
    Chen J, Brodsky SV, Goligorsky DM, et al.: Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res 2002, 90:1290–1298.PubMedCrossRefGoogle Scholar
  21. 21.
    Ceriello A, Mercuri F, Quagliaro L, et al.: Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001, 44:834–838.PubMedCrossRefGoogle Scholar
  22. 22.
    Laursen JB, Somers M, Kurz S, et al.: Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103:1282–1288.PubMedGoogle Scholar
  23. 23.
    Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108:1912–1916. Excellent review on basic mechanisms leading to cardiovascular injury.PubMedCrossRefGoogle Scholar
  24. 24.
    Szabo C, Mabley JG, Moeller SM, et al.: Part I: Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 2002, 8:571–580. This study suggests peroxynitrite as a new therapeutic target in diabetic vasculopathy.PubMedGoogle Scholar
  25. 25.
    Stalker TJ, Skvarka CB, Scalia R: A novel role for calpains in the endothelial dysfunction of hyperglycemia. FASEB J 2003, 17:1511–1513. This study demonstrates the important role of calpains in diabetic vascular inflammation leading to decreased NO, which could be pharmacologically prevented.PubMedGoogle Scholar
  26. 26.
    Venugopal SK, Devaraj S, Yuhanna I, et al.: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439–1441.PubMedCrossRefGoogle Scholar
  27. 27.
    Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endotheliumdependent vasodilatation in experimental diabetes. J Clin Invest 1991, 87:432–438.PubMedGoogle Scholar
  28. 28.
    Montagnani M, Ravichandran LV, Chen H, et al.: Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol 2002, 16:1931–1942.PubMedCrossRefGoogle Scholar
  29. 29.
    Osman AA, Pendergrass M, Koval J, et al.: Regulation of MAP kinase pathway activity in vivo in human skeletal muscle. Am J Physiol Endocrinol Metab 2000, 278:E992-E999.PubMedGoogle Scholar
  30. 30.
    Cusi K, Maezono K, Osman A, et al.: Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105:311–320.PubMedCrossRefGoogle Scholar
  31. 31.
    Federici M, Menghini R, Mauriello A, et al.: Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 2002, 106:466–472. This study presents evidence that elevated glucose via the hexosamine pathway impairs the PI3K-dependent insulin pathway leading to decreased eNOS activity, while the mitogenic branch remains unaffected.PubMedCrossRefGoogle Scholar
  32. 32.
    Sartipy P, Loskutoff DJ: Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003, 100:7265–7270.PubMedCrossRefGoogle Scholar
  33. 33.
    Matsubara M, Hayashi N, Jing T, Titani K: Regulation of endothelial nitric oxide synthase by protein kinase C. J Biochem (Tokyo) 2003, 133:773–781.Google Scholar
  34. 34.
    Inoguchi T, Sonta T, Tsubouchi H, et al.: Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003, 14:S227-S232.PubMedCrossRefGoogle Scholar
  35. 35.
    Nangle MR, Cotter MA, Cameron NE: Protein kinase C beta inhibition and aorta and corpus cavernosum function in streptozotocin-diabetic mice. Eur J Pharmacol 2003, 475:99–106.PubMedCrossRefGoogle Scholar
  36. 36.
    Tuttle KR, Anderson PW: A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 2003, 42:456–465.PubMedCrossRefGoogle Scholar
  37. 37.
    Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787–790.PubMedCrossRefGoogle Scholar
  38. 38.
    Du XL, Edelstein D, Dimmeler S, et al.: Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001, 108:1341–1348.PubMedCrossRefGoogle Scholar
  39. 39.
    Uemura S, Matsushita H, Li W, et al.: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001, 88:1291–1298.PubMedGoogle Scholar
  40. 40.
    Chen X, Touyz RM, Park JB, Schiffrin EL: Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001, 38:606–611.PubMedGoogle Scholar
  41. 41.
    Zhang L, Zalewski A, Liu Y, et al.: Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 2003, 108:472–478. This study demonstrates the mechanisms of ROS in diabetes leading, more than AGE-formation, to inflammatory gene expression.PubMedCrossRefGoogle Scholar
  42. 42.
    Vlassara H: The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001, 17:436–443.PubMedCrossRefGoogle Scholar
  43. 43.
    Kass DA, Shapiro EP, Kawaguchi M, et al.: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001, 104:1464–1470.PubMedGoogle Scholar
  44. 44.
    Makita Z, Radoff S, Rayfield EJ, et al.: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836–842.PubMedCrossRefGoogle Scholar
  45. 45.
    Bucciarelli LG, Wendt T, Qu W, et al.: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106:2827–2835. This study shows that RAGE contributes to accelerated lesion formation and progression in diabetic apoE-null mice.PubMedCrossRefGoogle Scholar
  46. 46.
    Ogihara T, Asano T, Ando K, et al.: Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002, 40:872–879.PubMedCrossRefGoogle Scholar
  47. 47.
    Kitada M, Koya D, Sugimoto T, et al.: Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003, 52:2603–2614.PubMedCrossRefGoogle Scholar
  48. 48.
    Desco MC, Asensi M, Marquez R, et al.: Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002, 51:1118–1124.PubMedCrossRefGoogle Scholar
  49. 49.
    Matsumoto S, Koshiishi I, Inoguchi T, et al.: Confirmation of superoxide generation via xanthine oxidase in streptozotocininduced diabetic mice. Free Radic Res 2003, 37:767–772.PubMedCrossRefGoogle Scholar
  50. 50.
    Petersen KF, Befroy D, Dufour S, et al.: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140–1142.PubMedCrossRefGoogle Scholar
  51. 51.
    Du X, Matsumura T, Edelstein D, et al.: Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003, 112:1049–1057. This study shows that PARP inhibition blocks several pathways of vascular damage in diabetes that are dependent on mitochondrial ROS generation.PubMedCrossRefGoogle Scholar
  52. 52.
    Endemann D, Pu Q, De Ciuceis C, et al.: Resistance arteries in type 2 diabetic patients under antihypertensive treatment show marked remodeling. Hypertension 2004, In press.Google Scholar
  53. 53.
    Schiffrin EL, Amiri F, Benkirane K, et al.: Peroxisome proliferatoractivated receptors: vascular and cardiac effects in hypertension. Hypertension 2003, 42:664–668.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Dierk H. Endemann
    • 1
  • Ernesto L. Schiffrin
    • 1
  1. 1.Clinical Research Institute of MontrealMontrealCanada

Personalised recommendations